# Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

> **NCT01814046** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Metastatic Ocular Melanoma
- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Aldesleukin
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Young Tumor Infiltrating Lymphocytes (TIL)

## Key facts

- **NCT ID:** NCT01814046
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-03-01
- **Primary completion:** 2017-05-01
- **Final completion:** 2017-05-31
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Investigator left the National Institutes of Health (NIH)
- **Last updated:** 2018-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01814046

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01814046, "Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01814046. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*